No Data
No Data
Ocular Therapeutix to Report First Quarter 2025 Financial Results on May 5, 2025
JMP Securities Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $19
Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $21
$OCUL Stock Is up 4% Today. Here's What We See in Our Data.
Piper Sandler Keeps Their Buy Rating on Ocular Therapeutix (OCUL)
Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
70581059 : a great buying opportunity in general. if the tariff stays, it has already been priced in. in case not, it will surge back.